FASIHA KANWAL to Cohort Studies
This is a "connection" page, showing publications FASIHA KANWAL has written about Cohort Studies.
Connection Strength
1.498
-
Inequalities in Developing Cirrhosis Complications Over Time: A Cohort Study. Am J Gastroenterol. 2025 Nov 01; 120(11):2548-2558.
Score: 0.117
-
Reply to: "Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea". J Hepatol. 2024 05; 80(5):e218-e219.
Score: 0.109
-
Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States. J Hepatol. 2022 02; 76(2):294-301.
Score: 0.092
-
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
Score: 0.080
-
Reply to: "Prevalence and short-term mortality in a national US cohort with acute-on-chronic liver failure". J Hepatol. 2019 09; 71(3):638-639.
Score: 0.079
-
Risk of Hepatocellular Cancer Recurrence in Hepatitis C Virus+ Patients Treated with Direct-Acting Antiviral Agents. Dig Dis Sci. 2019 11; 64(11):3328-3336.
Score: 0.078
-
Reply to: "Mortality of acute-on-chronic liver failure: What is the role of obesity?" J Hepatol. 2019 06; 70(6):1301-1302.
Score: 0.077
-
Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents. Aliment Pharmacol Ther. 2017 11; 46(10):992-1000.
Score: 0.070
-
Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
Score: 0.070
-
Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
Score: 0.067
-
Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
Score: 0.065
-
Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
Score: 0.061
-
Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clin Gastroenterol Hepatol. 2012 Nov; 10(11):1270-1277.e3.
Score: 0.049
-
Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011 Apr; 140(4):1182-1188.e1.
Score: 0.044
-
Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med. 2010 Aug 17; 153(4):231-9.
Score: 0.043
-
Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol. 2010 Jan; 8(1):79-84.
Score: 0.040
-
A comparison of liver transplantation outcomes in the pre- vs. post-MELD eras. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):169-77.
Score: 0.029
-
Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004 Sep; 99(9):1726-32.
Score: 0.028
-
Natural History of Indeterminate Liver Nodules in Patients With Advanced Liver Disease: A Multicenter Retrospective Cohort Study. Am J Gastroenterol. 2024 Nov 01; 119(11):2251-2258.
Score: 0.028
-
Hepatocellular Carcinoma Screening in a Contemporary Cohort of At-Risk Patients. JAMA Netw Open. 2024 04 01; 7(4):e248755.
Score: 0.028
-
Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort. JAMA Netw Open. 2022 07 01; 5(7):e2223504.
Score: 0.024
-
The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus. Clin Gastroenterol Hepatol. 2023 04; 21(4):1111-1113.e3.
Score: 0.024
-
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. Clin Gastroenterol Hepatol. 2023 02; 21(2):415-423.e4.
Score: 0.024
-
Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 03; 114(3):530-532.
Score: 0.019
-
Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019 04; 70(4):639-647.
Score: 0.019
-
Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol. 2018 01 04; 18(1):1.
Score: 0.018
-
Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017 03; 65(3):777-788.
Score: 0.017
-
Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol. 2017 02; 15(2):273-281.e1.
Score: 0.016
-
Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016 Jan; 14(1):124-31.e1.
Score: 0.015
-
Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015 Mar; 13(3):594-601.e1.
Score: 0.014
-
Increased risk of pancreatic adenocarcinoma after acute pancreatitis. Clin Gastroenterol Hepatol. 2014 Jul; 12(7):1143-1150.e1.
Score: 0.014
-
Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013 May; 57(5):1858-68.
Score: 0.013
-
Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012 Feb; 56(2):320-5.
Score: 0.011
-
Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies. Am J Transplant. 2005 Oct; 5(10):2433-40.
Score: 0.008
-
The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol. 2005 Oct; 100(10):2262-73.
Score: 0.008